Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression

Europace

Volumn 12, Issue 3, 2010, Pages 347-355

  Di Donna, Paolo ^a   Olivotto, Iacopo ^b   Delcrè, Sara Dalila Luisella ^a   Caponi, Domenico ^a   Scaglione, Marco ^a   Nault, Isabelle ^c   Montefusco, Antonio ^a   Girolami, Francesca ^b   Cecchi, Franco ^b   Haissaguerre, Michel ^c   Gaita, Fiorenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Atrial fibrillation; Genetics; Hypertrophic cardiomyopathy; Outcome; Radiofrequency ablation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLECAINIDE; SOTALOL; VERAPAMIL;

ADULT; AGE; ARTICLE; CATHETER ABLATION; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SARCOMERE; SINUS RHYTHM; SYMPTOM; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; GENOTYPE; HEART ATRIA; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 77749333435     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq013     Document Type: Article

References (27)

1. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650-5.
2. Erratum: JAMA 1999; 281(24):22887.
3. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygen BP et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301-7.
4. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-24.
5. Glancy DL, O'Brien KP, Gold HK, Epstein SE. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J 1970;32:652-9.
6. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;7:701-4.
7. Furlan AJ, Craciun AR, Raju NR, Hart N. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke 1984;15:282-4.
8. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003;42:30-2.
9. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990;15:1279-85.
10. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.
11. Oral H, Scharf C, Chugh A, Hall B, Cheung P, Good E et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003;108:2355-60.
12. Pappone C, Oreto G, Rosanio S, Vicedomini G, Tocchi M, Gugliotta F et al. Atrial electroanatomical remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001;104:2539-44.
13. Gaita F, Caponi D, Scaglione M, Montefusco A, Corleto A, Di Monte F et al. Longterm clinical results of two different ablation strategies in patients with paroxysmal and persistent atrial fibrillation. Circ Arrhythmia Electrophysiol 2008;1:269-75.
14. Gaita F, Di Donna P, Olivotto I, Scaglione M, Ferrero I, Montefusco A et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007;99:1575-81.
15. Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM et al. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2008;19:1009-14.
16. Kilicaslan F, Verma A, Saad E, Themistoclakis S, Bonso A, Raviele A et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 2006;3:275-80.
17. Losi MA, Betocchi S, Aversa M, Lombardi R, Mirando M, D'Alessandro G et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895-900.
18. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699-708.
19. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130-2.
20. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ et al., Heart Rhythm Society, European Heart Rhythm Association, European Cardiac Arrhythmia Society, American College of Cardiology, American Heart Association, Society of Thoracic Surgeons HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace 2007;9:335-79.
21. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
22. Ujino K, Barnes ME, Cha SS, Langins AP, Bailey KR, Seward JB et al. Twodimensional echocardiographic methods for assessment of left atrial volume. Am J Cardiol 2006;98:1185-8.
23. Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83:630-8.
24. Olivotto I, Maron BJ, Cecchi F. Pathophysiology and clinical consequences of atrial fibrillation in hypertrophic cardiomyopathy. In Maron BJ (ed.). Diagnosis and Management of Hypertrophic Cardiomyopathy. Massachusetts, USA: Blackwell Futura; 2004. p105-20.
25. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected nonreferral based patient population. Heart 1998;79:331-6.
26. Allessie MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001;103:769-77.
27. Sciagrà R, Sotgia B, Olivotto I, Cecchi F, Nistri S, Camici PG et al. Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. J Nucl Cardiol 2009;16:92-6. Epub 20 Jan 2009.